We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 12, 2021

Chronic Immune-Related AEs After Adjuvant Anti–PD-1 for High-Risk Resected Melanoma

JAMA Oncology

 

Additional Info

JAMA Oncology
Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
JAMA Oncol 2021 Mar 25;[EPub Ahead of Print], JR Patrinely, R Johnson, AR Lawless, P Bhave, A Sawyers, M Dimitrova, HL Yeoh, M Palmeri, F Ye, R Fan, EJ Davis, S Rapisuwon, GV Long, A Haydon, I Osman, JM Mehnert, MS Carlino, RJ Sullivan, AM Menzies, DB Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading